Windlas Biotech Limited Sets Nov 5 Board Meeting for Q2 FY27 Results

Windlas Biotech Limited will consider its unaudited standalone Q2 FY27 and first-half FY27 results on November 5, 2026, following reported sales of ₹248 crore in the June 2026 quarter. The company has also scheduled an investor conference call for November 6, while the September-quarter financial figures had not been disclosed in the cited filings.

When will Windlas Biotech announce Q2 FY27 results?

Windlas Biotech will hold a board meeting on November 5, 2026, to consider and approve unaudited standalone financial results for the quarter and half year ended September 30, 2026. The board-meeting intimation was filed with the exchanges on October 30, 2026.

The filing establishes the timing of the approval process but does not provide Q2 or H1 FY27 revenue, profit, margin, or other financial figures. Investors awaiting the September-quarter numbers will need to refer to the formal results filing issued after the board considers them.

The company’s earnings calendar also identifies November 5 as the upcoming earnings date. Its most recent listed earnings date was August 10, 2026, for Q1 FY27.

What will the November 6 investor call cover?

Windlas Biotech has scheduled a conference call at 11:30 AM IST on Friday, November 6, 2026, to discuss performance for Q2 and H1 FY27. The call will cover the quarter and half year ended September 30, 2026.

Managing Director Hitesh Windlass and CEO-CFO Komal Gupta are identified as the senior management participants for the call. The event gives shareholders and analysts a scheduled forum for management commentary after the board’s consideration of the financial statements.

The October 30 notice is procedural rather than a results announcement. It confirms the earnings-call schedule and does not disclose the company’s financial performance for the September quarter in advance.

What do Windlas Biotech’s recent quarterly numbers show?

Windlas Biotech reported sales of ₹248 crore for the quarter ended June 2026, according to the supplied quarterly-results table. This was 4.03% higher quarter on quarter and 18.09% higher year on year in the provided earnings summary.

Operating profit for the June 2026 quarter was ₹27 crore, compared with ₹25 crore in March 2026 and ₹27 crore in June 2025. Expenses were ₹221 crore in June 2026, against ₹213 crore in the preceding quarter.

Earlier, the supplied Q4 FY26 summary placed revenue at ₹238.50 crore, up 2.32% quarter on quarter from ₹233.10 crore and 17.66% year on year. The quarterly table presents sales rounded to ₹238 crore for March 2026, which is consistent with the summary’s rounded presentation.

Why does the Q2 FY27 filing matter to investors?

Windlas Biotech’s September-quarter filing will provide the next official update after the June-quarter sales figure of ₹248 crore. It will also cover the first half of FY27, allowing investors to assess the two-quarter standalone financial performance disclosed by the company.

The available quarterly series shows sales increasing from ₹145 crore in June 2023 to ₹248 crore in June 2026. Over the same period, operating profit moved from ₹17 crore to ₹27 crore, although it was ₹24 crore in December 2025 before recovering to ₹25 crore in March 2026 and ₹27 crore in June 2026.

The current notices do not provide a forecast, business outlook, or guidance for the September quarter. Therefore, the reported figures and management commentary following the results release will be the relevant official disclosures for evaluating the period.

What governance and compliance updates has Windlas Biotech disclosed?

Windlas Biotech said its trading window was closed from October 1, 2026 and will reopen 48 hours after the declaration of the financial results. The company stated that this follows the SEBI regulations on prohibition of insider trading.

Separately, the company announced board changes effective October 12, 2026. Aashish Mehra and Soni Saran Singh were appointed as independent directors for five-year terms, while Vivek Dhariwal resigned as independent director and board chairman due to personal reasons.

These governance disclosures are distinct from the Q2 financial-results process. However, they form part of the company’s recent exchange communication ahead of the board meeting and investor call.

Conclusion

Windlas Biotech has set November 5 for board consideration of its Q2 and H1 FY27 standalone results and November 6 for management’s investor call. The latest available quarterly data in the supplied material shows June 2026 sales of ₹248 crore and operating profit of ₹27 crore, while the September-quarter numbers remain undisclosed.

Investors should watch for the formal exchange filing after the November 5 board meeting and the management discussion scheduled for 11:30 AM IST on November 6. The disclosures may clarify Q2 and first-half financial performance, which the current procedural notices do not quantify.